CDK
Les inhibiteurs des kinases dépendantes des cyclines (CDK) sont des composés qui bloquent l'activité des CDK, un groupe de kinases protéiques qui régulent le cycle cellulaire, la transcription et d'autres processus cellulaires. Les CDK sont activées par leur liaison aux cyclines, et leur activité est cruciale pour la progression des cellules à travers les différentes phases du cycle cellulaire. Inhiber les CDK peut arrêter la division cellulaire, entraînant un arrêt du cycle cellulaire et l'apoptose, en particulier dans les cellules cancéreuses où les CDK sont souvent dysrégulées. Les inhibiteurs de CDK sont largement utilisés dans la recherche sur le cancer et ont un potentiel thérapeutique dans le traitement de divers cancers. Chez CymitQuimica, nous offrons une sélection complète d'inhibiteurs de CDK de haute qualité pour soutenir vos recherches sur le contrôle du cycle cellulaire, le cancer et le développement thérapeutique.
500 produits trouvés pour "CDK"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
NU6140
CAS :<p>NU6140 is a selective inhibitor of CDK2-cyclin A (IC50, 0.41 μM).</p>Formule :C23H30N6O2Degré de pureté :98.33%Couleur et forme :SolidMasse moléculaire :422.52CDK4/6-IN-2
CAS :<p>CDK4/6-IN-2 是一种CDK4和CDK6抑制剂，IC50分别为 2.7 和 16 nM。</p>Formule :C27H32F2N8Degré de pureté :99.47%Couleur et forme :SolidMasse moléculaire :506.59Trilaciclib hydrochloride
CAS :<p>Trilaciclib hydrochloride (G1T28 hydrochloride) is an inhibitor of CDK4/6 (IC50s: 1 nM and 4 nM for CDK4 and CDK6).</p>Formule :C24H32Cl2N8ODegré de pureté :99.69% - 99.89%Couleur et forme :SolidMasse moléculaire :519.47Nimbolide
CAS :<p>Nimbolide, from neem, inhibits CDK4/6, NF-κB, Wnt, PI3K-Akt, MAPK, JAK-STAT pathways and induces apoptosis.</p>Formule :C27H30O7Degré de pureté :95.84% - 99.4%Couleur et forme :SolidMasse moléculaire :466.52hSMG-1 inhibitor 11j
CAS :<p>hSMG-1 inhibitor 11j: pyrimidine, IC50=0.11 nM, >455x selective vs. mTOR/PI3Kα/γ/CDK1/CDK2; cancer research use.</p>Formule :C27H28ClN7O3SDegré de pureté :99.22% - 99.65%Couleur et forme :SolidMasse moléculaire :566.07NVP-2
CAS :<p>NVP-2 selectively inhibits CDK9 (IC50: 0.514 nM), prompts apoptosis, and affects other CDKs (IC50: 0.584-0.706 μM).</p>Formule :C27H37ClN6O2Degré de pureté :99.13%Couleur et forme :SolidMasse moléculaire :513.07Garcinone C
CAS :<p>Garcinone C, a xanthone from Garcinia oblongifolia, is anti-inflammatory, promotes healing, and may fight some cancers.</p>Formule :C23H26O7Degré de pureté :99.13% - 99.92%Couleur et forme :SolidMasse moléculaire :414.45(R)-CR8
CAS :<p>(R)-CR8 ((R)-Isomer) is a potent and selective CDK inhibitor.</p>Formule :C24H29N7ODegré de pureté :98.41%Couleur et forme :SolidMasse moléculaire :431.53Lerociclib dihydrochloride
CAS :<p>Lerociclib dihydrochloride (G1T38 dihydrochloride) is a potent and selective inhibitor of CDK4/CDK6, with IC50s of 2 nM and 1 nM for CDK6/CyclinD3 and CDK4/</p>Formule :C26H36Cl2N8ODegré de pureté :97.4%Couleur et forme :SolidMasse moléculaire :547.52Simurosertib
CAS :<p>Simurosertib (TAK-931) is a selective and ATP-competitive cell division cycle 7 kinase inhibitor (IC50: <0.3 nM).</p>Formule :C17H19N5OSDegré de pureté :99.93% - 99.93%Couleur et forme :SolidMasse moléculaire :341.43CDKI-73
CAS :<p>CDKI-73: strong CDK9 blocker, Ki 4 nM, kills CLL cells selectively, aids cisplatin.</p>Formule :C15H15FN6O2S2Degré de pureté :98.11%Couleur et forme :SolidMasse moléculaire :394.45BRD6989
CAS :<p>BRD6989, a cortistatin A analog, inhibits CDK8/19, enhances IL-10, and binds CDK8 with a 200 nM IC50.</p>Formule :C16H16N4Degré de pureté :99.43%Couleur et forme :SolidMasse moléculaire :264.33CDK2-IN-4
CAS :<p>CDK2-IN-4 is a potent and selective inhibitor of CDK2 with an IC50 of 44 nM for CDK2/cyclin A.</p>Formule :C23H18N6O2SDegré de pureté :97.24% - 99.10%Couleur et forme :SolidMasse moléculaire :442.49Avotaciclib
CAS :<p>Avotaciclib (BEY1107) is a potent and orally active cyclin dependent kinase 1 (CDK1) inhibitor.Avotaciclib can be used to study locally advanced or metastatic</p>Formule :C13H11N7ODegré de pureté :98.02%Couleur et forme :SolidMasse moléculaire :281.27Cyclin K degrader 1
<p>Cyclin K degrader 1 is a Cyclin K degrader.Cyclin K degrader 1 is a degrader converted from AT-7519.Cyclin K degrader 1 has weak degrading activity against Cyclin K but does not result in a sustained decrease in degradation affinity.Cyclin K degrader 1 is a degrader converted from AT-7519.</p>Formule :C23H17Cl2N5O2Degré de pureté :99.76%Couleur et forme :SolidMasse moléculaire :466.32(±)-Enitociclib
CAS :<p>(±)-Enitociclib ((±)-BAY-1251152) is a racemic mixture of BAY-1251152. BAY-1251152 is highly selective inhibitor of PTEF/CDK9.</p>Formule :C19H18F2N4O2SDegré de pureté :99.29%Couleur et forme :SolidMasse moléculaire :404.43Samuraciclib hydrochloride
CAS :<p>Samuraciclib HCl is an oral CDK7 inhibitor (IC50: 41 nM), 45-230x selective over CDK1/2/5/9, inhibiting breast cancer growth (GI50: 0.2-0.3 μM).</p>Formule :C22H31ClN6ODegré de pureté :98.99% - 99.8%Couleur et forme :SolidMasse moléculaire :430.97Ribociclib succinate
CAS :<p>Ribociclib succinate (LEE011 succinate) is a highly specific CDK4/6 inhibitor (IC50: 10 nM and 39 nM, respectively).</p>Formule :C27H36N8O5Degré de pureté :99.9%Couleur et forme :SolidMasse moléculaire :552.63MBQ-167
CAS :<p>MBQ-167 is a dual inhibitor of Rac/Cdc42 (IC50s: 103 nM for Rac 1/2/3 and 78 nM for Cdc42 in MDA-MB-231 cells, respectively).</p>Formule :C22H18N4Degré de pureté :98.07% - 99.52%Couleur et forme :SolidMasse moléculaire :338.41Amantadine hydrochloride
CAS :<p>Amantadine hydrochloride (CI-719) is an antiviral that is used in the prophylactic or symptomatic treatment of influenza A and Parkinson disease.</p>Formule :C10H18ClNDegré de pureté :99.98%Couleur et forme :Solid CrystallineMasse moléculaire :187.71XPW1
CAS :<p>XPW1 is a CDK9 inhibitor with antitumor activity, inhibits DNA repair procedures, and can be used for the research of clear cell renal cell carcinoma.</p>Formule :C36H39ClFN7O2Degré de pureté :98.08%Couleur et forme :SoildMasse moléculaire :656.19Cirtuvivint
CAS :<p>Cirtuvivint (SM08502) is a potent and orally active CDC-like kinase (CLK) inhibitor that can be used to study arthritis.</p>Formule :C24H25N7ODegré de pureté :99.46% - >99.99%Couleur et forme :SolidMasse moléculaire :427.5Ca2+ channel agonist 1
CAS :<p>Ca2+ channel agonist 1 activates N-type Ca2+ channels and inhibits Cdk2 (EC50: 14.23 μM/3.34 μM) for motor nerve issues.</p>Formule :C19H26N6ODegré de pureté :97.71%Couleur et forme :SolidMasse moléculaire :354.45CDK12-IN-6
CAS :<p>CDK12-IN-6, a pyrazolotriazine, strongly inhibits CDK12 (IC50 1.19 μM at 2 mM ATP), but not CDK2/Cyclin E or CDK9/Cyclin T1 (both IC50 >20 μM).</p>Formule :C20H21F2N9Couleur et forme :SolidMasse moléculaire :425.448(E/Z)-THZ1 2HCl
CAS :<p>THZ1 2HCl: selective CDK7 allosteric inhibitor, IC50 3.2 nM, hinders cancer cell growth.</p>Formule :C31H30Cl3N7O2Degré de pureté :99.51%Couleur et forme :SolidMasse moléculaire :638.98[pSer2, pSer5, pSer7]-CTD TFA
<p>Substrate '[pSer2, pSer5, pSer7]-CTD (TFA)' for CDK7 phosphorylates RNA Pol II CTD at ser2, 5, 7.</p>Formule :C98H138F3N21O39Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :2291.25EGFR/CDK2-IN-3
<p>EGFR/CDK2-IN-3 (compound 4b) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 71.7 nM and 113.7 nM, respectively.</p>Formule :C30H20N6OSDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :512.58FDA-Approved Kinase Inhibitor Library
<p>A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.</p>Couleur et forme :Liquid(1S,3R,5R)-PIM447 dihydrochloride
<p>(1S,3R,5R)-PIM447 (dihydrochloride) an inhibitor of PIM(IC50 of 0.095 μM for Pim1, 0.522 μM for Pim2 and 0.369 μM for Pim3).</p>Formule :C24H25Cl2F3N4ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :513.38PP-C8
<p>PP-C8: PROTAC CDK12-Cyclin K degrader with DC50s 416/412 nM; synergizes with PARP inhibitor against TNBC.</p>Formule :C43H51FN12O7Couleur et forme :SolidMasse moléculaire :866.94BSJ-03-204
CAS :<p>BSJ-03-204 is a selective Cdk4/6 degrader.</p>Formule :C43H48N10O8Couleur et forme :SolidMasse moléculaire :832.9dCeMM3
CAS :<p>dCeMM3 is a glue degrader that induces ubiquitination and degradation of cyclin K by promoting CDK12-cyclin K interaction with CRL4B ligase.</p>Formule :C14H11ClN4OSDegré de pureté :98.48% - 99.41%Couleur et forme :SolidMasse moléculaire :318.78JH-XI-10-02
CAS :<p>JH-XI-10-02 selectively degrades CDK8 (IC50: 159 nM) through proteasome, sparing CDK8 mRNA and CDK19.</p>Formule :C53H69N5O9Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :920.161CDK2-IN-43
<p>CDK2-IN-43 (Compound 3a) is a CDK2-cyclin E2 inhibitor with an IC50 value of 6.0 nM. It is applicable to cancer research.</p>Formule :C19H27N7OCouleur et forme :SolidMasse moléculaire :369.464CDK4/6-IN-5
CAS :<p>CDK4/6-IN-5 inhibits CDK4/6; Ki: 0.2 nM (CDK4/D1) & 4.4 nM (CDK6/D3). (WO2019207463A1, A93)</p>Formule :C22H28ClFN6O4SCouleur et forme :SolidMasse moléculaire :527.01CDK4/6-IN-23
<p>CDK4/6-IN-23 (Compound 42) is a potent and selective inhibitor of CDK4/6, displaying an IC50 of 11 nM for CDK6. This compound significantly activates immune cells and enhances IL-3 production. In mice undergoing 5-FU chemotherapy, CDK4/6-IN-23 demonstrates dual bone marrow protection and immunomodulatory effects.</p>Formule :C32H34FN7O4Couleur et forme :SolidMasse moléculaire :599.655BLINK15
<p>BLINK15 is a blood-brain barrier-permeable Cdk5 inhibitor. It reduces CDK5 activity in CDK5/p35 (IC50= 29.34 nM) and CDK5/p25 (IC50= 12.08 nM) complexes. Additionally, BLINK15 exhibits antidiabetic and neuroprotective effects. It lowers blood glucose levels in type 2 diabetes (T2D) mice, enhances cognitive abilities, and diminishes neurodegenerative lesions.</p>Couleur et forme :Odour SolidCDK5-IN-1
CAS :<p>CDK5-IN-1: Potent CDK5 inhibitor (<10 nM) used in kidney disease research.</p>Formule :C24H25FN6O3SCouleur et forme :SolidMasse moléculaire :496.56CDK12/13-IN-2
<p>CDK12/13-IN-2 (Compound 24) is a covalent inhibitor of CDK12 and CDK13, exhibiting IC50 values of 15.5 nM and 12.2 nM, respectively. It effectively inhibits the proliferation of breast cancer cells and can be utilized in the research of triple-negative breast cancer.</p>Formule :C24H22FN7O2Couleur et forme :SolidMasse moléculaire :459.48BSJ-04-132
<p>Selective Cdk4 degrader. Degrades Cdk4 in Molt-4 cells, with no effect on Cdk6 levels. Displays cereblon-dependent degradation.</p>Couleur et forme :LiquidJH-XVI-178
CAS :<p>JH-XVI-178: potent CDK8/19 inhibitor with good pharmacokinetics, low clearance, moderate oral bioavailability.</p>Formule :C22H22ClN7OCouleur et forme :SolidMasse moléculaire :435.92CDK9 inhibitor HH1
CAS :<p>CDK9 inhibitor HH1 (8019-9719) is an inhibitor of the human CDK2-cyclin A2 complex with an IC50 value of 2 μM.</p>Formule :C13H15N3OSDegré de pureté :99.92%Couleur et forme :SolidMasse moléculaire :261.34IV-361
CAS :<p>IV-361, an orally active and selective CDK7 inhibitor with a Ki value of less than or equal to 50 nM, demonstrates potent anti-cancer activity (US20190256531A1</p>Formule :C23H32FN5O2SiCouleur et forme :SolidMasse moléculaire :457.625CDK2/PIM1-IN-1
<p>CDK2/PIM1-IN-1 is an inhibitor of the kinases CDK2 (IC50: 0.27 μM) and PIM1 (IC50: 0.67 μM). It can induce apoptosis (cell death) and reduce the expression of TNF-α, which promotes tumors. CDK2/PIM1-IN-1 exhibits antitumor activity.</p>Couleur et forme :Odour SolidLL-K8-22
<p>LL-K8-22: potent CDK8/cyclin C degrader; DC50 ~2.5μM; hinders STAT1 phosphorylation; curbs E2F/MYC cancer pathways; for TNBC study.</p>Formule :C37H43N5OCouleur et forme :SolidMasse moléculaire :573.77PROTAC CDK9 degrader 4
CAS :<p>PROTAC CDK9 degrader 4 is a CDK9 degrader that targets transcriptional regulation and has potential anticancer activity.</p>Formule :C43H56N10O5Couleur et forme :SolidMasse moléculaire :792.97EGFR/CDK2-IN-2
<p>EGFR/CDK2-IN-2 (compound 6a) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 19.6 nM and 87.9 nM, respectively.</p>Formule :C49H32N12O2S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :884.99CDK7-IN-7
CAS :<p>CDK7-IN-7: Selective CDK7 inhibitor, IC50 < 50 nM (Patent CN112661745A).</p>Formule :C20H20BrF3N6O2Couleur et forme :SolidMasse moléculaire :513.319EGFR/CDK2-IN-4
<p>EGFR/CDK2-IN-4 (compound 4c) is a dual inhibitor targeting EGFR and CDK-2, demonstrating IC50 values of 89.6 nM for EGFR and 165.4 nM for CDK-2.</p>Formule :C24H16N6OS2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :468.55Multi-target kinase inhibitor 2
<p>Compound 5K (Multi-target kinase inhibitor 2) is a multi-targeted kinase inhibitor demonstrating activity against EGFR, Her2, VEGFR2, and CDK2 with IC50 values</p>Degré de pureté :98%Couleur et forme :Odour Solid
